ArticleCell death and differentiation2026
TRIM17 downregulation modulates CRPC progression and enzalutamide resistance by derepressing BCL2 expression via the p53-dependent and p53-independent pathways.
Article in Cell death and differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The failure of second-generation antiandrogen drugs such as enzalutamide (ENZ) treatment indicates that prostate cancer (PCa) can progress to castration-resistant prostate cancer (CRPC). CRPC is considered the terminal stage of PCa and currently has no effective treatment options due to drug resistance. However, the underlying mechanism of ENZ- resistance in CRPC remains unclear. Here, we conducted a single-cell transcriptomic analysis in combination with a gene module clustering assessment to identify the regulatory genes enriched along the hormone-sensitive PCa and CRPC trajectories. This approach revealed that tripartite motif-containing 17 (TRIM17) is a specific time-dependent gene and key regulator that is expressed at significantly low levels in CRPC cells but at high levels in nonresistant epithelial PCa cells. Analysis of patient-derived clinical specimens and in vitro functional experiments demonstrated that TRIM17 low expression could promote CRPC progression and ENZ resistance. Moreover, TRIM17 activation markedly inhibited CRPC progression and enhanced the sensitivity of CRPC cells to ENZ. Mechanistically, TRIM17 binds to and ubiquitinates B-cell lymphoma-2 (BCL2) directly to mediate its degradation. On the other hand, TRIM17 represses BCL2 by inhibiting p53 degradation by TRIM28. The stabilization of p53 suppresses BCL2 expression and interferes with the abundance and signaling of BCL2 in CRPC cells, further inhibiting CRPC progression and conveying ENZ resensitivity. Importantly, the TRIM17 activator pioglitazone, a registered drug for type 2 diabetes, could synergize with ENZ to reverse ENZ resistance and amplify its cytotoxic effects on CRPC cells. In conclusion, this study identifies a previously undefined function of TRIM17 to modulate ENZ sensitivity and reveals that activation of TRIM17 has great potential as a promising therapeutic strategy for ENZ- resistant PCa, indicating that TRIM17 can serve as a biomarker to guide the treatment of CRPC.
Identifiers
42288623What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.